SOHM India Signs Strategic Alliance With Injectable Manufacturing Unit

SOHM India Signs Strategic Alliance With Injectable Manufacturing Unit Increasing Generic Drug and Pharmaceutical Product Offerings to 279 
 
SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories announced today that is has signed a strategic alliance with an injectable manufacturing unit in India. The alliance adds 89 injectable and drops based generic pharmaceutical products and include additional manufacturing capacity. The product line for the SOHM brand has now reached 279.

Our product line continues to grow and we have maintained a steady increase in revenue driven by the continued commitment of our staff in India and here in the U.S.," stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. "As we expand our sales force and distribution channels we have also increased marketing activities to support our growing product lines. Strategic alliances and the addition of our newly added manufacturing capacity has been a key component in allowing fulfillment of order flow as we increase and diversify our private label product offerings."

About SOHM, Inc.

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Email Contact

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.